Calreticulin

Gene

Related News

Novel Anti-CD47 Fusion Protein CO-005 Overcomes Rituximab Resistance in Lymphoma Models

Jun 19, 2026

CO-005, a humanized anti-CD47 fusion protein from Caedo Oncology, showed potent antitumor activity in preclinical models of B-cell lymphoma, including rituximab-resistant tumors. The therapy induces programmed cancer cell death while disrupting immune checkpoints, offering a potential solution to CD20 resistance.

Cancer care advances through UAB research and AdvanCell radiopharmaceutical development

Apr 20, 2026

UAB researchers are advancing cancer prevention, tumor targeting and precision ablation, while AdvanCell is developing targeted alpha therapy and a prostate cancer drug in Phase 1 trials. Both efforts focus on new treatment approaches and research infrastructure.